Stephen Young's Online Journal

I think entries like Stephen's are what Heidi had in mind when she wrote the value and vagaries of external links.

Anyone want to buy a bridge?

Stephen, please provide a link or citation (if not online) for this million dollar AIDS cure.

This disease affects poorer countries more than it does wealthier countries like America, but it is starting to become prevalent worldwide.

It was prevelant worldwide along time ago.

The treatments mentioned in this article seem failry effective and do not cost $1million.

I think many of you misunderstood what the message of my blog was trying to convey. It wasn't arguing about whether there is a reliable cure for AIDS or whether AIDS is more prevalent now then it was in the 1980's. I do realize that many of you are just trying to get last minute points by commenting on others blogs. However this paper was focusing on how pharmaceutical companies have to effectively manage the final product's costs, or else the product will not be successful. But I appreciate the fact that you wasted several hours of your time to try to think of something critical to say about my entry.

What are you basing your entry on? You have cited no article, book, or new story for the claims you have presented.

You do realize your entries are open to the whole world and not just classmates that need to earn points?

You link still does not mention a cure with a 90% effective rate, nor a $1 million price per treatment.

Steve,
You are right that many of us misunderstood the intent of your entry. Perhaps if you began with the closing sentence, "A major problem pharmaceutical companies are having is not finding a cure for a ravaging disease, but rather to make it affordable for their customers to buy," you could then have led us through the issues facing the companies. Another possibility would have been to start with something like:

"While people throughout the world die from illnesses for which their are no cures, many continue to suffer or die from diseases that do have treatments or cures. Their suffering continues because we have not yet found a way to contain the costs of pharmaceutical research, production and distribution. Thus, many of the more successful treatments are only available to those who can pay the price..."

By posing your premise at the beginning, we readers can then more easily watch as your discussion of the topic evolves. Then you could add links judiciously in places where they can offer additional data or deeper insight into the issues you propose.

While your focus is primarily in regards to the pharmaceutical companies, you may also find it interesting to read the Reducing Health Disparities blog. Good luck with your blogging project.

I recently received a comment from a friend claiming that this entry has nothing to do with Management 250. Well Scott, it might appear that way, but becoming an effective manager means that you are able to efficiently run your company. We learned this two wednesdays ago. This efficiency, in return, has positive consequences such as reduced costs, greater production, etc. These medical companies, who are trying to discover a medicine for a certain disease, have to focus on the cost as well as the cure.

Steve, although your entry was controversial, I agree with its intent. Once the Pharmaceutical companies have a final product to market, it has proven to be difficult for them to figure out a reasonabe cost to charge for their product. If they were to charge an inflated amount, sales would decrease. If they charge to deflated amount, sales would also decrease because consumers would view the product as generic. It's difficult for the Pharmaceutical companies to find a middle of the road, fair amount to charge consumers for their new products.

wtnphse krpiftv zohugielq zglf kjeop gmrojwa qmrikvlxa